Dilpacimab

Dilpacimab (ABT165) is a potent dual-variable domain immunoglobulin, targets both delta-like ligand 4 (DLL4) and VEGF pathways.. Dilpacimab can be used in research of cancer[1].

Product Specifications

CAS Number

[1791420-09-1]

Product Name Alternative

ABT165; PR1283233

UNSPSC

12352203

Target

VEGFR

Type

Inhibitory Antibodies

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/dilpacimab.html

Purity

96.88

Solubility

10 mM in DMSO

Smiles

[Dilpacimab]

Molecular Weight

(199.12 kDa)

References & Citations

[1]Gordon MS, et, al. Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors. Mol Cancer Ther. 2021 Oct;20 (10) :1988-1995.